Kazia Therapeutics in the NEWS 
Sydney, July 10, 2024, Kazia Therapeutics Limited (KZIA) - an oncology-focused drug development company, is pleased to announce results from GBM-AGILE, a phase II/III study that included an evaluation of paxalisib versus standard of care (SOC) for patients with the life-threatening brain cancer glioblastoma. 
GBM AGILE STUDY
GBM AGILE is an adaptive phase . . .